Biotech Law Blog

The Prinz Law Office has launched The California Biotech Law Blog in order to provide in-depth analysis and commentary on legal developments, dealmaking, legislation, and industry events of interest to the California biotech law community.

Click here to view The California Biotech Law Blog, or read recent blog highlights below:

• Presidential Politics: More on the McCain Healthcare Reform Plan
• U.S. Supreme Court Petition Challenges Constitutionality of Patent Appeals Judge Appointments
• Senate Passes Legislation Banning Genetic Discrimination
• SBIR/STTR Reauthorization Act Passes in House; Biotech Industry is Big Winner
• California Supreme Court Overturns Punitive Damage Award Against Genentech
• San Diego Consortium for Regenerative Medicine to Build $115 Million Stem Cell Research Facility in San Diego
• Biotech Companies Running into Roadblocks in Entering into Deals with the UC System
• U.S. Supreme Court Postpones Decision on Review of Patent Rights Case; Seeks Input from Bush Administration
• Patent Reform Bill Stalled in Senate
• Takeda Acquires Millennium Pharmaceuticals for $8.8. Billion
• CV Therapeutics Signs Lucrative Deal with TPG-Axon Capital
• Billionaire Investor Carl Icahn Files Suit Against Biogen
• Patent Office to Consider Appeal of Ruling Which Voided Patent Rule Changes
• BIO Spent $6.6 Million on Lobbying Efforts in 2007
• Doctor Conflicts: Should the Public Be Concerned About Bias Against the Drug Companies Rather than Just the Possibility of Bias In Favor of Drug Companies
• Cell Genesys Closes $320 Million Deal with Takeda
• House Committee Holds Hearing to Consider Modernizing the SBIR Program
• VaxGen Terminates Merger Agreement; Liquidation May Soon Follow
• Gilead Sciences Overtakes Amgen as World's Second Most Highly Valued Biotech
• Canadian Drug Company Biovail Settles SEC Accounting Fraud Charges
• Are Rushed Approvals by the FDA Responsible for the Recent Rash of Drug Problems?
• Do Investors Dislike Biotech Alliances?
• Class Action Suit To Test Whether Drug Companies Have Legal Duty to Class Members for Money Spent on Off-Label Uses of Generic
• Congress to Consider Legislation Requiring Doctor Disclosure of Gifts Received from Drug Companies
• California Files Suit Against Abbott Laboratories for Scheme to Block Generic
• Fraud Charges Filed Against Former InterMune CEO
• Update on the Implementation of New Legislation to Expand Federal Clinical Trial Disclosure Laws
• USPTO Proposes Rule Change to Require Biological Deposits
• Presidential Politics: What is the McCain Plan for Healthcare Reform?
• New Bill to Provide Biotech Companies Sarbanes-Oxley Relief
• USPTO Upholds WARF Stem Cell Patent Claim
• Stem Cell Companies Looking Ahead to New Administration
• FTC to Test Legality of "Pay for Delay" Settlements
• More Evidence that Outsourcing is on the Rise in the Biotech Industry
• California Governor Views California's Experience with Stem Cell Research as Providing a Strong Example for Other States to Follow
• FDA to Collaborate with Congress on Developing Follow-On Biologics Legislation
• Stem Cell Research in CA: Providing a Lesson for Other States
• Debating the Future of the SBIR Program
• Supreme Court Declines to Hear Case on Experimental Drugs
• Pfizer to Discontinue Sales of Inhaled Insulin Drug Exubera
• Health Advocacy Groups and Medical Specialty Groups Lobby Congress to Change SBIR Rules on Eligibility
• Federal Circuit Imposes New Limits on Willful Infringement
• Biogenerics Legislation to be Tabled in 2007
• Patent Reform Bill Passed In House
• Kristie Prinz Interviewed by Dow Jones Marketwatch on Patent Holding Companies, Patent Reform
• Congress to Consider SBIR Funding Increase
• FDA Exercising New Caution in Approving Drugs
• Biotech Takes Steps to Fight Generic Threat
• Genzyme's Example of Myozyme: A Case Study of Why Biogenerics Legislation is a Bad Idea?
• California's Stem Cell Priorities: Is the State Ahead of its Time or Was the Vote a Reactionary Political Decision?
• Court Ruling Denies Terminally Ill Patients the Right to Unapproved But Potentially Life-Saving Drugs
• Stanford, UC Representatives Offer Insights on Licensing with their Universities
• Biotech vs. High Tech: Opposing Views on Patent Reform
• Case Study for Potential Impact of New Generics Legislation?
• USPTO to Reconsider Patents on HIV Drug Viread
• Biotech Exit Strategy Dependent on Mergers & Acquisitions Over IPOs
• ViaCell Wins Infringement Suit Over PharmaStem
• House Declines to Address Generics Provisions of FDA Legislation
• California Stem Cell Agency Funds Controlled By Conflicts of Interest
• Strategy Examined on How Patent Holders are Delaying Market Entrance by Generics
• Latest on Biotech Valuations
• California Biotech Companies Rally Behind Proposed New Tax Legislation
• New Challenge to Biotech Industry
• California Stem Cell institute Plan Revealed on Distributing the Research Money
• Professor Predicts Biotechnology Will Have Key Role in Future
• Sky Radio's Dennis Michael Interviews Kristie Prinz on Biotech Industry Developments
• Big-Cap Biotech Stocks Taking Hit on Wall Street
• Senate Committee Approves New Generics Legislation
• LexBlog Interviews California Biotech Law's Kristie Prinz
• President Bush Vetoes Latest Stem Cell Bill
• California Healthcare Institute Warns State Biotech Industry at Risk
• Another Look at MedImmune v. Genentech
• Another New Investor Jumps on the Biotech Bandwagon
• Key Issues to Consider in Biotech Licensing
• New Report Says Outsourcing on the Rise in Life Sciences Industry
• Google's New Interest in Biotech
• Industry Group Sends Letter to Congress on Patent Reform
• Stem Cell Suits Dismissed By California Supreme Court
• New Study Urges Caution in Anticipating Stem Cell Research Payoff
• Tech Transfer Office Culture Preventing Commercialization of Technology
• Senate Passes Stem Cell Funding Bill
• Bay Area Venture-Funded Life Science Companies Increase Valuations
• The Ethics of Paying to Continue a Clinical Trial
• Stem Cell Bills Set to Be Debated in Senate
• USPTO Rejects WARF Stem Cell Patents Claim on Re-Examination
• Both Sides of Biologics Debate Explored in Marketplace Money Feature
• Outsourcing Trends in the Biotech Industry
• Five Biotech Companies to Watch
• Top Five Regions Targeting Biotech Companies
• Bill Proposed to Establish California Office of Intellectual Property
• New Biotech Trend: Private Equity Investing
• Angel Investing Reported to Be Up in 2007
• HR 1561: The Enhancing Drug Safety and Innovation Act of 2007
• Case for Patent Reform
• Affymetrix Wins Verdict Against Illumina
• Victory for Stem Cell Research in California
• Biotech Companies Testing the Open Source Model
• Genentech Claims Rejected on Patent which was Subject of Recent Supreme Court Decision
• Potential Impact of New Generics Bill
• New Victory for Stem Cell Research